The GRETA™ platform represents a cutting-edge technological frontier in drug discovery, merging proprietary biological assays with advanced machine learning algorithms. This synergy enables rapid, high-resolution analyses of cellular changes in response to drug treatments, pushing the boundaries of conventional drug development practices.